EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study

Varalee Yodsurang iD, Krit Wattanathum iD, Thanate Srimatimanon iD, Krittin Pitinanon iD, Andro Ranti iD, Pattaraporn Siripattarachai iD, Piyapha Hirunpatrawong iD, Voravut Rungpradubvong iD, Seiichi Sakamoto iD, Alisara Sangviroon Sujarit iD

Therapeutic Advances in Drug Safety · 2026-05 · 17

DOI: 10.1177/20420986261452545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 29.05.2026. Verfasst von Varalee Yodsurang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Faculty of Pharmaceutical Sciences Fund, Chulalongkorn University, The Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While bleeding is an inherent risk of all anticoagulant therapies, individual susceptibility varies considerably. Rivaroxaban, a direct oral anticoagulant widely used for thromboembolic prevention, is associated with substantial interindividual variability in bleeding risk, posing an ongoing clinical challenge.

Objectives

To investigate associations between pharmacogenetic variants in five pharmacokinetic (PK) and nine pharmacodynamic (PD) genes, along with clinical factors, and bleeding outcomes in Thai patients receiving rivaroxaban.

Design

A retrospective case–control study was conducted among 91 patients with atrial fibrillation, including 27 who experienced bleeding events.

Methods

Genetic variants in PK and PD genes were genotyped using the MassARRAY ® system, and associations between pharmacogenetic variants, clinical factors, and bleeding risk were evaluated using logistic regression analysis.

Results

The CT genotype of ABCB1 rs10276036 (C>T) was associated with an increased risk of bleeding. Clinical factors, including prior bleeding history, were also significantly associated with increased bleeding risk. In addition, allele frequency patterns suggested population-specific genetic variation in this Thai cohort. These findings suggest that genetic and clinical factors may jointly contribute to bleeding susceptibility.

Conclusion

Bleeding risk in Thai patients receiving rivaroxaban appeared to be influenced by both pharmacogenetic variants, particularly the ABCB1 rs10276036, and established clinical factors. These findings are exploratory and highlight the potential value of integrating genetic and clinical information for risk stratification, pending validation in larger cohorts.

Trial registration

As a retrospective non-interventional study, this work was not registered in a clinical trial registry. Ethical approval was obtained (COA No. 1657/2022).

Schlagwörter

Stichwörter der Autor:innen

bleedingpharmacodynamicpharmacogeneticpharmacokineticrivaroxaban

Autor:innen und Institutionen

  • Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Preclinical Toxicity and Efficacy Assessment of Medicines and Chemicals, Chulalongkorn University, Bangkok, Thailand.
  • Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
  • Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Cardiac Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

ORCID-Profile: Varalee Yodsurang, Krit Wattanathum, Thanate Srimatimanon, Krittin Pitinanon, Andro Ranti, Pattaraporn Siripattarachai, Piyapha Hirunpatrawong, Voravut Rungpradubvong, Seiichi Sakamoto, Alisara Sangviroon Sujarit

Förderung

  • The Faculty of Pharmaceutical Sciences Fund, Chulalongkorn University
  • The Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University

Zitieren

APA

Yodsurang, V., Wattanathum, K., Srimatimanon, T., Pitinanon, K., Ranti, A., Siripattarachai, P., Hirunpatrawong, P., Rungpradubvong, V., Sakamoto, S., & Sujarit, A. S. (2026). Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study. Therapeutic Advances in Drug Safety, 17. https://doi.org/10.1177/20420986261452545

Vancouver

Yodsurang V, Wattanathum K, Srimatimanon T, Pitinanon K, Ranti A, Siripattarachai P, et al. Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study. Therapeutic Advances in Drug Safety. 2026;17. doi:10.1177/20420986261452545

BibTeX
@article{Yodsurang2026,
  author = {Yodsurang, Varalee and Wattanathum, Krit and Srimatimanon, Thanate and Pitinanon, Krittin and Ranti, Andro and Siripattarachai, Pattaraporn and Hirunpatrawong, Piyapha and Rungpradubvong, Voravut and Sakamoto, Seiichi and Sujarit, Alisara Sangviroon},
  title = {Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study},
  journal = {Therapeutic Advances in Drug Safety},
  year = {2026},
  volume = {17},
  doi = {10.1177/20420986261452545}
}
Kostenlos starten →